GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL宣佈，阿斯利康贊助的與第一三共共同進行的TROPION-Lung12第3期研究中，首位患者已接受其非小細胞肺癌ctDNA檢測資格測試。
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
GRAIL宣佈，在阿斯利康與第一三共合作贊助的Tropion-Lung12三期研究中，首位患者已通過其非小細胞肺癌ctDNA測定進行了資格測試
資訊熱榜
更新時間